Last updated on March 2020

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies

Brief description of study

This is a single-arm, open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.

Detailed Study Description

The study may enroll up to 95 subjects in total.

Clinical Study Identifier: NCT04035434

Find a site near you

Start Over

Research Site 3

Melbourne, Australia
  Connect »